Cáncer de pulmón microcítico. Otros tumores torácicosmesotelioma, timoma y tumores germinales mediastínicos

  1. González, J.L. López
  2. Expósito, F. Navarro
  3. Losada, C.
  4. Castillo, C.
  5. Soto, M. Álvarez-Mon
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2017

Título del ejemplar: Enfermedades oncológicas (I) Cáncer de pulmón. Cáncer de cabeza y cuello

Serie: 12

Número: 31

Páginas: 1825-1832

Tipo: Artículo

DOI: 10.1016/J.MED.2017.04.002 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

Resumen Cáncer microcítico de pulmón Se trata de un tumor característico de personas muy fumadoras, y supone el 15% del total de los cánceres de pulmón. A diferencia del cáncer no microcítico de pulmón. Su tratamiento es fundamentalmente la quimioterapia y la radioterapia concomitantes en estadio limitado, y la quimioterapia en estadios diseminados. Mesotelioma Neoplasia infrecuente de mal pronóstico con una supervivencia media de entre 6 y 18 meses. El carcinógeno principal implicado en su desarrollo es el asbesto. Aproximadamente el 20% de los pacientes serán candidatos a cirugía con resección macroscópica completa (R0) o parcial (R1). Para los no candidatos a cirugía la mejor opción es la quimioterapia paliativa o con intención neoadyuvante. Timoma Se trata de un tumor infrecuente que se origina en el timo. El tratamiento de elección es quirúrgico, con resección en bloque de la tumoración, y posteriormente radioterapia posoperatoria en casos seleccionados. Para tumores irresecables la radioterapia puede ser de utilidad en algunos casos, y en otros la quimioterapia con intención paliativa. Tumores germinales mediastínicos Son tumores germinales que aparecen en el mediastino sin que haya evidencia de neoplasia ovárica o testicular primaria. La estrategia terapéutica difiere enormemente en función de la histología, siendo suficiente en algunos casos solo la cirugía, mientras que en otros es imprescindible la quimioterapia.

Referencias bibliográficas

  • Gaspar LE, Gay EG, Crawford J, Putnam JB, Herbst RS, Bonner JA. Limited stage small cell lung cancer (stages I-III): observations from the National Cancer Data Base. Clin Lung Cancer. 2005;6:355.
  • Ettinger DS, Berkey BA, Abrams RA, Fontanesi J, Machtay M, Duncan PJ. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice daily thoracic radiotherapy for patients with limited-stage small cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study. J Clin Oncol. 2005;23:4991.
  • Horn L, Bernardo P, Sandler A, Wagner H, Levitan N, Levitt ML. A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): a trial of the Eastern Cooperative Oncology Group. J Thorac Oncol. 2009; 4:527.
  • Baas P, Belderbos JS, Senan S, Kwa HB, van Bochove A, van Tinteren H. Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study. Br J Cancer. 2006;94:625.
  • Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV. Carboplatin or cisplatin based chemotherapy in first line treatment of small cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30:1692.
  • Corso CD, Rutter CE, Park HS, Lester-Coll NH, Kim AW, Wilson LD. Role of chemoradiotherapy in elderly patients with limited-stage small-cell lung cancer. J Clin Oncol. 2015;33:4240.
  • Okamoto H, Watanabe K, Kunikane H, Yokoyama A, Kudoh S, Asakawa T. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer. 2007;97:162.
  • Spiro SG, James LE, Rudd RM, Trask CW, Tobias JS, Snee M, et al. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis. J Clin Oncol. 2006;24:3823.
  • Pijls-Johannesma MC, De Ruysscher D, Lambin P, Rutten I, Vansteenkiste JF. Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev. 2005;CD004700.
  • De Ruysscher D, Pijls-Johannesma M, Bentzen SM, Minken A, Wanders R, Lutgens L. Time between the first day of chemo-therapy and the last day of chest radiation is the most important predictor of survival in limited disease small cell lung cancer. J Clin Oncol. 2006;24:1057.
  • Ready N, Pang HH, Gu L, Gregory A, Sachdev P, Antonius A. Chemotherapy with or without maintenance sunitinib for untreated extensive stage small cell lung cancer: a randomized, double-blind, placebo controlled phase ii study—CALGB 30504 (Alliance). J Clin Oncol. 2015;33(15):1660-5.
  • Lee SM, Woll PJ, Rudd R, Ferry D, O’Brien M, Middleton G. Antiangiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo controlled trial. J Natl Cancer Inst. 2009;101:1049.
  • Spigel DR, Hainsworth JD, Yardley DA, Raefsky E, Patton J, Peacock N. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol. 2010;28:43.
  • Arnold AM, Seymour L, Smylie M, Ding K, Ung Y, Findlay B. Phase II study of vandetanib or placebo in small cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol. 2007;25:4278.
  • Giaccone G, Debruyne C, Felip E, Chapman PB, Grant SC, Millward M. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited disease small cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol. 2005;23:6854.
  • Rusch VW, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D. Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol. 2012;7:1631.
  • Kao SC, Yan TD, Lee K, Henderson DW, Klebe S, Kennedy C. Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma. J Thorac Oncol. 2011;6:602.
  • American Joint Committee on Cancer. Pleural mesothelioma. Cancer staging manual. 7ª ed. New York: Springer; 2010. p. 271.
  • Pass HI, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D. Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee. J Thorac Oncol. 2014;9:856.
  • Gill RR, Richards WG, Yeap BY, Matsuoka S, Wolf AS, Gerbaudo VH. Epithelial malignant pleural mesothelioma after extrapleural pneumo-nectomy: stratification of survival with CT-derived tumor volume. AJR Am J Roentgenol. 2012;198:359.
  • Rice D, Rusch V, Pass H, Asamura H, Nakano T, Edwards J. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group. J Thorac Oncol. 2011;6:1304.
  • Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27:3007.
  • Weder W, Stahel RA, Bernhard J, Bodis S, Vogt P, Ballabeni P. Multicenter trial of neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol. 2007;18:1196.
  • Filosso PL, Evangelista A, Ruffini E, Rendina EA, Margaritora S, Novellis P. Does myasthenia gravis influence overall survival and cumulative incidence of recurrence in thymoma patients? A Retrospective clinicopathological multicentre analysis on 797 patients. Lung Cancer. 2015; 88:338.
  • Marom EM. Advances in thymoma imaging. J Thorac Imaging. 2013;28:69.
  • Treglia G, Sadeghi R, Giovanella L, Cafarotti S, Filosso P, Lococo F. Is (18)F-FDG PET useful in predicting the WHO grade of malignancy in thymic epithelial tumors? A meta-analysis. Lung Cancer. 2014; 86:5.
  • Abdel Razek AA, Khairy M, Nada N. Diffusion weighted MR imaging in thymic epithelial tumors: correlation with World Health Organization classification and clinical staging. Radiology. 2014;273:268.
  • Safieddine N, Liu G, Cuningham K, Tsao Ming, Hwang D, Brade A. Prognostic factors for cure, recurrence and long-term survival after surgical resection of thymoma. J Thorac Oncol. 2014;9:1018.
  • Hamaji M, Ali SO, Burt BM. A meta-analysis of surgical versus nonsurgical management of recurrent thymoma. Ann Thorac Surg. 2014;98:748.
  • Marina N, London WB, Frazier AL, Stephen L, Frederick R, Barbara C. Prognostic factors in children with extragonadal malignant germ cell tumors: a pediatric intergroup study. J Clin Oncol. 2006;24:2544.
  • Aguirre D, Nieto K, Lazos M, Rocio Peña Y, Icela Palma MS, Susana Kofman-Alfaro. Extragonadal germ cell tumors are often associated with Klinefelter syndrome. Hum Pathol. 2006;37:477.
  • Völkl TM, Langer T, Aigner T, Greess H, Beck JD, Rauch AM. Klinefelter syndrome and mediastinal germ cell tumors. Am J Med Genet A. 2006;140:471.
  • Kesler KA, Rieger KM, Hammoud ZT, Kruter LE, Perkins SM, Turrentine MW. A 25-year single institution experience with surgery for primary mediastinal nonseminomatous germ cell tumors. Ann Thorac Surg. 2008;85:371.
Fuente de los datos: Dialnet